Trisalus Life Sciences Inc (TLSI) Stock Price, Quote & News

Latest News on TLSI

Mar 30, 2025, 8:02 AM EDT - 20 days ago

TriSalus Life Sciences: Optimistic Guidance For 2025, But There Are Still Risks

Mar 27, 2025, 2:02 PM EDT - 23 days ago

TriSalus Life Sciences, Inc. (TLSI) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 7:30 AM EDT - 23 days ago

TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update

Mar 26, 2025, 8:00 AM EDT - 24 days ago

TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav® Infusion System Mapping

Mar 6, 2025, 8:00 AM EST - 6 weeks ago

TriSalus Life Sciences® Announces That Its Researchers Received Two JVIR Top Paper Awards for the Publication of “Intra-arterial Pressure-Enabled Drug Delivery™ Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model”

Feb 3, 2025, 4:05 PM EST - 2 months ago

TriSalus Life Sciences Announces Key Appointments to Board of Directors

Feb 3, 2025, 8:00 AM EST - 2 months ago

TriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMed

Jan 23, 2025, 8:00 AM EST - 3 months ago

TriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results and Conference Call

Jan 9, 2025, 8:00 AM EST - 3 months ago

TriSalus Life Sciences® Announces Publication of Pre-Clinical Data Demonstrating Improved Delivery of Embospheres® to Liver Tumors using Pressure-Enabled Drug Delivery™ (PEDD™) via the TriNav® Infusion System

Dec 24, 2024, 11:29 AM EST - 4 months ago

TriSalus Life Sciences: Continuing To Maintain Optimism As Costs Are Cut

Nov 14, 2024, 10:22 AM EST - 5 months ago

TriSalus Life Sciences, Inc. (TLSI) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 8:00 AM EST - 5 months ago

TriSalus Reports Q3 2024 Financial Results and Provides Business Update

Nov 11, 2024, 7:00 AM EST - 5 months ago

TriSalus Life Sciences® Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav® Infusion System to U.S. Veterans with Liver Cancer

Nov 7, 2024, 7:00 AM EST - 5 months ago

TriSalus Life Sciences Launches TriNav® LV Infusion System and TriGuide™ Guiding Catheters, Expanding Portfolio of PEDD™ Devices for Improved Tumor Treatment

Oct 31, 2024, 8:00 AM EDT - 6 months ago

TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call

Oct 14, 2024, 4:05 PM EDT - 6 months ago

TriSalus Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit

Sep 26, 2024, 7:00 AM EDT - 7 months ago

TriSalus Life Sciences Announces Appointment of Riad Salem, M.D., to its Scientific Advisory Board

Sep 23, 2024, 7:00 AM EDT - 7 months ago

TriSalus Announces Journal of Vascular and Interventional Radiology Publication of Data that Demonstrate Improved Therapeutic Delivery of Glass Microspheres to Solid Tumors With PEDD™ Method via the TriNav® Infusion System

Aug 15, 2024, 2:33 PM EDT - 8 months ago

TriSalus Life Sciences, Inc. (TLSI) Q2 2024 Earnings Call Transcript

Aug 15, 2024, 8:00 AM EDT - 8 months ago

TriSalus Reports Q2 2024 Financial Results and Business Update

Aug 1, 2024, 7:00 AM EDT - 9 months ago

TriSalus Life Sciences to Host Second Quarter 2024 Financial Results Conference Call

Jul 1, 2024, 4:00 PM EDT - 10 months ago

TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation

Jun 26, 2024, 5:45 PM EDT - 10 months ago

TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants

Jun 25, 2024, 3:17 PM EDT - 10 months ago

TriSalus Life Sciences: Falling Despite Moving Forward Into The Market

Jun 3, 2024, 7:00 AM EDT - 11 months ago

TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting

May 24, 2024, 6:05 AM EDT - 11 months ago

TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants

May 15, 2024, 11:40 AM EDT - 1 year ago

TriSalus Life Sciences, Inc. (TLSI) Q1 2024 Earnings Call Transcript

May 15, 2024, 8:00 AM EDT - 1 year ago

TriSalus Reports Q1 2024 Financial Results and Business Update

May 7, 2024, 7:00 AM EDT - 1 year ago

TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors

May 6, 2024, 4:58 PM EDT - 1 year ago

TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call

Apr 30, 2024, 4:35 PM EDT - 1 year ago

TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth Initiatives

Apr 1, 2024, 10:56 AM EDT - 1 year ago

TriSalus Life Sciences, Inc. (TLSI) Q4 2023 Earnings Call Transcript

Apr 1, 2024, 8:00 AM EDT - 1 year ago

TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update

Mar 26, 2024, 8:00 AM EDT - 1 year ago

TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting

Mar 21, 2024, 8:00 AM EDT - 1 year ago

TriSalus Life Sciences Announces Oral Presentations at the Upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting

Mar 11, 2024, 5:15 PM EDT - 1 year ago

TriSalus Life Sciences Announces Q4 Conference Call and Preliminary and Unaudited Q4 and Full Year 2023 Financial Results

Mar 7, 2024, 7:00 AM EST - 1 year ago

TriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Association's Adopted Name Council for “Nelitolimod” as the Nonproprietary Drug Name for SD-101

Feb 29, 2024, 7:00 AM EST - 1 year ago

TriSalus Life Sciences Announces Real-World Data Demonstrating the Ability of TriNav® to Successfully Treat Patients with Higher Disease Burden and to Improve Delivery of Therapeutics to Liver Tumors

Jan 24, 2024, 12:48 PM EST - 1 year ago

TriSalus Life Sciences: Rocket-Like Recovery Could Be An Inflection Point

Dec 14, 2023, 7:00 AM EST - 1 year ago

TriSalus Life Sciences Announces CMS Reimbursement for the TriNav® Infusion System via Assignment of a New Technology Healthcare Common Procedure Coding System (HCPCS) Code

Nov 14, 2023, 8:00 AM EST - 1 year ago

TriSalus Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 7, 2023, 4:05 PM EST - 1 year ago

TriSalus Life Sciences to Host Third Quarter 2023 Financial Results Conference Call

Nov 4, 2023, 2:25 PM EDT - 1 year ago

Late-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC 2023 Supports Development of Innovative Immuno-oncology Approach for Liver and Pancreas Indications

Nov 3, 2023, 12:00 PM EDT - 1 year ago

TriSalus Life Sciences Presents Data for SD-101 Delivered by TriSalus Infusion System for Pancreatic Adenocarcinoma at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 25, 2023, 9:05 AM EDT - 1 year ago

TriSalus Life Sciences Announces Late Breaker and Additional Data Presentations on Liver Metastases and Pancreatic Cancer at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Aug 10, 2023, 4:05 PM EDT - 1 year ago

TriSalus Life Sciences Completes Merger with MedTech Acquisition Corporation

Aug 2, 2023, 5:00 PM EDT - 1 year ago

MedTech Acquisition Corporation Adjourns Special Meeting of Stockholders

Jun 12, 2023, 7:00 AM EDT - 2 years ago

TriSalus Life Sciences Presents Additional Data for SD-101 Delivered by the Proprietary PEDD™ Method with the TriNav™ Device for Uveal Melanoma Liver Metastases at the ASCO 2023 Annual Meeting

Apr 20, 2023, 7:00 AM EDT - 2 years ago

TriSalus Life Sciences Presents New Data at AACR for SD-101 Delivered by the Proprietary PEDD™ Method in Stage IV Uveal Melanoma Patients With Liver Metastases

Feb 21, 2023, 7:00 AM EST - 2 years ago

Market Cap	175.03M
Revenue (ttm)	29.43M
Net Income (ttm)	-30.05M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-102.11%
Debt to Equity Ratio	-1.06

Volume	15,500
Avg Vol	53,720
Day's Range	N/A - N/A
Shares Out	30.49M
Stochastic %K	93%
Beta	0.49
Analysts	Strong Sell
Price Target	$11.50